Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.65 |
| ▸ | CA1 | P00915 | 5/20 | 0.65 |
| ▸ | CA12 | O43570 | 3/20 | 0.65 |
| ▸ | CA9 | Q16790 | 3/20 | 0.65 |
| ▸ | CA3 | P07451 | 2/20 | 0.65 |
| ▸ | CA4 | P22748 | 2/20 | 0.65 |
| ▸ | CA6 | P23280 | 2/20 | 0.65 |
| ▸ | CA5A | P35218 | 2/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.65 |
| ▸ | MMP1 | P03956 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29715252 | 0.82 | CA2 (0.65) | CA2CA1CA12CA9CA5A | |
| SCHEMBL6417364 | 0.82 | CA2 (0.56) | CA2CA1CA12CA9CA3 | |
| SCHEMBL14676346 | 0.82 | CA2 (0.56) | CA2CA1CA12CA9CA3 | |
| SCHEMBL18739981 | 0.82 | CA2 (0.65) | CA2CA1CA12CA9CA5A | |
| SCHEMBL15199343 | 0.79 | ACHE (0.53) | CA2CA1CA12CA9CA3 | |
| SCHEMBL10448367 | 0.79 | CA2 (0.55) | CA2CA1CA12CA9CA3 | |
| SCHEMBL25619820 | 0.79 | CA2 (0.61) | CA2CA1CA12CA9CA3 | |
| SCHEMBL526906 | 0.79 | CA2 (1.00) | CA2CA1CA12CA9CA3 | |
| SCHEMBL28729020 | 0.78 | TSHR (0.52) | CA2CA1CA12CA9CA3 | |
| SCHEMBL17526121 | 0.78 | ALDH1A1 (0.59) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903015-A | Process for the preparation of N-fluoro-N-alkylsulfonamides | 中国科学院上海有机化学研究所 | 2024-04-19 | — | — | CN | claimed |
| EP-4719413-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | Animol Discovery, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092070-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY INC (US) | 2026-04-02 | — | — | US | disclosed |
| WO-2024246837-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-117903015-A | Process for the preparation of N-fluoro-N-alkylsulfonamides | 中国科学院上海有机化学研究所 | 2024-04-19 | — | — | CN | disclosed |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20200407328-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2020-12-31 | — | — | US | disclosed |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-08-10 | — | — | US | disclosed |
| US-20090012307-A1 | Process for the Preparation of 4-(imidazol-1-yl)benzenesulfonamide Derivatives | PALAU PHARMA, S.A. (ES) | 2009-01-08 | — | — | US | disclosed |
| EP-1424329-B1 | PROCESS FOR THE PREPARATION OF 4-(IMIDAZOL-1-YL)BENZENESULFONAMIDE DERIVATIVES | PALAU PHARMA SA (ES) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008060927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008060927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-7351836-B2 | Antiinflammatory agents | PALAU PHARMA, S.A. (ES) | 2008-04-01 | — | — | US | disclosed |
| US-20040242872-A1 | Method of preparing 4-(imidazole-1-yl)benzenesulphonamide derivatives | PALAU PHARMA, S.A. (ES) | 2004-12-02 | — | — | US | disclosed |
| EP-1424329-A1 | METHOD OF PREPARING 4-(IMIDAZOLE-1-IL)BENZENESULPHONAMIDE DERIVATIVES | J. Uriach & Cia. S.A. (ES) | 2004-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407328-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | CA2 4824/4885CA1 4861/4885CA12 4724/4885 |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | CA2 4578/4885CA1 4242/4885CA12 3487/4885 |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | CA2 4824/4885CA1 4861/4885CA12 4724/4885 |
| US-20090012307-A1 | Process for the Preparation of 4-(imidazol-1-yl)benzenesulfonamide Derivatives | IL1B, IL1A, TBXAS1 | CA2 4485/4885CA1 4776/4885CA12 4864/4885 |
| US-20040242872-A1 | Method of preparing 4-(imidazole-1-yl)benzenesulphonamide derivatives | IL1B, IL1A, IRAK1 | CA2 4236/4885CA1 4607/4885CA12 4864/4885 |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | CA2 4752/4885CA1 4832/4885CA12 4743/4885 |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | CA2 4824/4885CA1 4861/4885CA12 4724/4885 |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | CA2 4752/4885CA1 4832/4885CA12 4743/4885 |
| US-20260092070-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | JAK1, JAK3, JAK2 | CA2 1072/4885CA1 2926/4885CA12 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.